Pan-neurodegeneration proteomics reveals disease subtypes and molecular signatures.

Lower body parkinsonism: rethinking MRI planimetry.

Fronto-medial theta instability error signal correlates with postural sway in Parkinson's disease and progressive supranuclear palsy.

Natural Killer Subset Changes and Vascular Endothelial Growth Factor-A Plasma Profile in Progressive Supranuclear Palsy: The NKscape Study.

[Basal ganglia and movement disorders : Part 1: the parkinsonian spectrum-Neuroradiological patterns and diagnostic considerations].

Unveiling discrepancies in depression detection among persons with dementia: A comparative analysis of caregiver and self-report.

Bilateral reverse shoulder arthroplasty in a patient with progressive supranuclear palsy: a case report.

[A case of progressive supranuclear palsy with progressive non-fluent agrammatic variant primary progressive aphasia who could sing fluently].

Chronological Diagnostic Algorithm Predicting Neuropathology in Parkinsonism.

Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration.

Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.

GV1001 reduces pathological 4R tau and functional deficits in models relevant to progressive supranuclear palsy.

Plasma tau-species positive neuron-derived extracellular vesicles in progressive supranuclear palsy.

Longitudinal Videofluorographic Dysphagia Measures in Progressive Supranuclear Palsy.

Transcriptomic signature of frontotemporal lobar degeneration with TDP-43 type C pathology.

Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial.

REM sleep behavior disorder as a shared motor phenotype: A multidimensional clinical study.

Frontotemporal lobar degeneration-TDP mimicking progressive supranuclear palsy: A perspective on clinicopathology, genetics, and biomarkers.

Improving access to care through transportation and internet use for patients with atypical parkinsonism: A pilot study.

Short tandem repeat expansions in patients with neurodegenerative dementia.

[MRI in neurodegenerative Parkinsonian syndromes].

Revisiting Minamata disease through computational phenotypic similarity analysis.

Longitudinal Evaluation of Polyneuropathy in Atypical Parkinsonian Syndromes.

Functional MRI in Multiple System Atrophy: A Promising Biomarker for Clinical Applications.

Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI-2620 PET.

Association between the prevalence of neurological diseases and the density of board-certified neurologists: ecological cross-sectional analysis.

Incidence and Survival Rates of Frontotemporal Lobar Degeneration: Population-Based Registry Study.

Novel Variants in DCTN1 Associated with Perry Disease: A Case Series from a Chinese Parkinsonism Cohort.

Accuracy of clinical diagnosis in neurodegenerative diseases - a study of 455 autopsy cases.

A data-driven SSM/PCA analysis approach for differential diagnosis of parkinsonism using 11C-PE2I PET.

Nanoscopic tau aggregates are not shared intermediates but disease-specific entities across tauopathies.

Juggling Under Controlled Hypoxia as a Multimodal Coordinative and Cognitive Training in Parkinson's Disease-A Narrative Review.

Artificial microRNAs targeting tau enable post-symptomatic functional recovery in aged tauopathy mice.

Progressive Supranuclear Palsy PERK haplotype B selectively translates DLX1 promoting tau toxicity.

Clinical implications of progressive ventilatory impairment in multiple system atrophy and progressive supranuclear palsy.

Executive anosognosia in progressive supranuclear palsy versus Parkinson's disease.

Vulnerability of anterior cingulate Von Economo neurons to FTLD-tauopathies in behavioral variant frontotemporal dementia.

Dementia with Lewy bodies and additional progressive supranuclear palsy presenting with early postural instability and frequent falls: an autopsy case.

Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.

Suicide attempt by a patient with an early phase of progressive supranuclear palsy: a case report.

Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.

Classification of tauopathies from human brain homogenates through salt-modulated tau amplification.

Reduced synaptic density in patients with progressive supranuclear palsy: An 18F-SynVest-1 PET study.

Cholinergic substrates of gait and postural impairments in Progressive Supranuclear Palsy.

Multi-model Diffusion MRI Signatures in Atypical Parkinsonian Disorders.

Patient-reported Vision Quality-of-life in Parkinsonian Syndromes and Ataxias and Association with Clinical Oculomotor Findings.

Real-world evaluation of Armstrong's criteria in corticobasal degeneration: Phenotypic overlap and diagnostic challenges.

Balancing Accuracy and Precision: Optimal b-values for Diffusion Tensor Imaging Along the Perivascular Space.

Current Neuroimaging Modalities to Distinguish Parkinson's Disease from its Mimics: Imaging Features and Implications for Clinical Practice.

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation.

Automated differentiation of parkinsonian disorders: an ROI-based analysis of subcortical shape and cortical surface features.

Molecular features of human pathological tau distinguish tauopathy-associated dementias.

Percutaneous endoscopic gastrostomy in atypical parkinsonian syndromes: survival and aspiration outcomes from a retrospective international cohort.

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.

Oculogyric crisis induced by high-dose apomorphine in a patient with advanced Parkinson's disease.

Retinal Thickness Profiles in Parkinsonian Syndromes: Discerning Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy via Optical Coherence Tomography.

Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.

Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration.

Subtracting First Principal Component May Improve 4R Tau Detectability on [18F]Flortaucipir Tau PET.

Dysphagia and Dysarthria in Neurodegenerative Diseases: A Multisystem Network Approach to Assessment and Management.

Localized Iron Deposition and Shape Changes of Cerebellar Dentate in Progressive Supranuclear Palsy Clinical Variants.

Dementia in Progressive Supranuclear Palsy: A Narrative Review.

Brainstem and Cerebellar Volume Loss and Associated Clinical Features in Progressive Supranuclear Palsy.

Hydrocephalus should not be a mandatory exclusion criterion in PSP: Emerging pathologic and clinical evidence urges reconsideration.

Rapidly progressive dysphagia and vertical supranuclear gaze palsy: a key diagnostic clue for progressive supranuclear palsy in Levodopa-Resistant parkinsonism.

Moving beyond the hospital: in-depth characterization of daily-life mobility in patients with atypical Parkinsonian disorders.

Revealing the conformational landscape of tau P → L mutants in R23 tau macromolecule: A pathway to targeted therapeutic design.

Voice and Speech in Atypical Parkinsonian Disorders.

First Korean Case of C9orf72-Related Amyotrophic Lateral Sclerosis With Progressive Supranuclear Palsy-Like Features.

CORTICOBASAL SYNDROME PRESENTING AS A PROGRESSIVE HEMIPARETIC SYNDROME: A CASE REPORT.

Association between Physical Function at Discharge and Fall Frequency One Month after Discharge in Patients with Progressive Supranuclear Palsy.

Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy: a randomized, remote, double-blinded, 6-week cross-over design study protocol comparing zolpidem, suvorexant, and placebo.

Wernicke's encephalopathy unmasking progressive supranuclear palsy and Alzheimer's pathology: a diagnostic challenge in an older adult.

The spectrum of movement disorders in neurosyphilis: A systematic review.

Refining a mouse model of progressive supranuclear palsy through inoculation of human post-mortem brain-derived tau.

PET evaluation of cholinergic system differences in progressive supranuclear palsy and age-matched controls using [18F]VAT.

4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy.

18 F-FDG, 18 F-FP-CIT, and 18 F-Florzolotau PET Imaging in Progressive Supranuclear Palsy : Region-Specific Correlations Between Glucose Metabolism, Dopaminergic Function, and Tau Pathology.

The Utility of Olfactory Testing to Discriminate Parkinson's Disease From Diagnostic Mimics: A Systematic Review and Meta-Analysis.

Praja1 E3 ubiquitin ligase and the role it plays in neurodegeneration.

Inflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.

Unlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer's Disease and Other Tauopathies.

Distinct plasma inflammatory signatures reflect disease severity and progression in progressive supranuclear palsy: a prospective cohort study.

Between Habit and Mannerism: Idiosyncratic Motor Behavior.

Paraneoplastic progressive Supranuclear palsy: a case report and literature review.

White matter hyperintensities in the deep cerebral venous territory differ between subcortical and cortical 4-repeat tauopathies.

Plasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy.

The Paper-Toss Test: enhancing bedside recognition of corticobasal syndrome.

Progressive Supranuclear Palsy With Post-traumatic Frontal Lobe Damage Mimicking Anti-IgLON5 Antibody Disease.

Deep Learning-Based Brainstem Segmentation and Multi-Class Classification for Parkinsonian Syndrome.

Increased 18F-AV1451 Retention in Soft Tissue of Patients With Progressive Supranuclear Palsy.

Brain atrophy and cholinergic denervation in progressive supranuclear palsy: an MRI and [18F]-FEOBV PET study.

Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy.

Clinical Framework for Motor Rehabilitation in Parkinsonism: Integrating Individualized and Syndrome-Specific Approaches.

Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.

Patient with Progressive Supranuclear Palsy Initially Diagnosed as Anxiety and Depression.

Progressive supranuclear palsy and corticobasal syndrome: cross-sectional study of palliative care needs.

Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.

Quantification of Neuromelanin as a Neuroimaging Biomarker for Parkinson's Disease.

Comparative [18F]Florzolotau and [18F]FDG PET Imaging Patterns in Anti-IgLON5 Disease and Progressive Supranuclear Palsy.

NDPACX: a newly defined X-linked Parkinsonian syndrome associated with SLC9A6 hemizygote mutation.

Progressive Supranuclear Palsy or Something More? Unveiling Late-Onset Wilson's Disease.

Updates of nuclear medicine imaging in neurodegenerative disorders.

Neurofilament light chain as a diagnostic and prognostic biomarker in atypical parkinsonisms: current evidence, new data, challenges, and future directions.

Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report.

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review.

Single-cell Spatial Transcriptional Profiling Uncovers Heterogeneous Cellular Responses to Pathogenic Tau in a Mouse Model of Neurodegeneration.

Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis.

Beyond Parkinson's Disease: A Narrative Review of Neuromelanin MRI in Neurodegenerative Diseases.

Methodological considerations for MRI biomarkers in progressive supranuclear palsy.

ERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies.

Patterns of Longitudinal Regional Brain Atrophy in Patients With Different Progressive Supranuclear Palsy Clinical Variants.

The Role of MRI in Capturing Phenotypic Variability in Progressive Supranuclear Palsy: Lessons for Future Clinical Trials.

Acoustic Vowel Metrics as Correlates of Dysphagia and Dysarthria in Brainstem Neurodegenerative Diseases.

Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementia.

Remote Cortical Network for Frontal Cognitive Symptoms Derived from Tau Accumulation in Progressive Supranuclear Palsy.

Interpeduncular Angle: A Possible Marker to Differentiate Atypical Parkinsonism from Idiopathic Parkinson's Disease.

Duloxetine for PSP-Related Speech Disorders.

FTLD-MAPT mutations and short 5'UTR Tau mRNAs increase Tau translation.

Dynamic multi-scale deep learning with mixture of experts for differentiating iNPH and PSP using MRI.

Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy.

Backward walking as a mobility assessment and exercise intervention for persons with neurologic disorders: A scoping review.

The genetic landscape of frontotemporal lobar degeneration: investigation of a diagnostic cohort of 2747 probands.

Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in Healthy Participants.

Association between visual hallucinations and α-synuclein oligomers in patients with dementia with Lewy bodies.

Multiple System Atrophy Without Dysautonomia: An Autopsy-Confirmed Study.

TDP-43-proteinopathy at the crossroads of tauopathy: on copathology and current and prospective biomarkers.

Potential Role of Transferrin and Vascular Cell Adhesion Molecule 1 in Differential Diagnosis Among Patients with Tauopathic Atypical Parkinsonian Syndromes.

Automated MRI-Based Classification of Parkinsonism: A Deep Learning Approach to Distinguish PD From PSP.

Deep transcranial magnetic stimulation in progressive supranuclear palsy: a randomized double-blind, cross-over study.

Levodopa exposure and nigral neuroinflammation in parkinsonian disorders: A postmortem study of 63 cases.

Refining the diagnostic accuracy of Parkinsonian disorders using metaphenomic annotation of the clinicopathological literature.

Progressive supranuclear palsy-like parkinsonism ensuing from anti-N-methyl-Daspartate receptor encephalitis.

Proximity Labeling of the Tau Repeat Domain Enriches RNA-Binding Proteins That Are Altered in Alzheimer's Disease and Related Tauopathies.

Data-Driven differentiation of idiopathic Normal-Pressure hydrocephalus and progressive supranuclear palsy via automated volumetric analysis.

The discriminative linguistic profiles of progressive supranuclear palsy and Parkinson's disease.

Peripheral immunity patterns, imaging features, and clinical outcomes in patients with gait impairment and ventriculomegaly on brain MRI.

Intracellular trafficking SNARE protein, syntaxin-6, modifies prion cellular phenotypes and risk of disease development in vivo.

Utility of Locus Coeruleus Signal Intensity on High-resolution T1-weighted MR Imaging with Magnetization Transfer for Differentiating Parkinson's Disease from Atypical Parkinsonism.

Leveraging Proteomics to Explore the Molecular Mechanisms of Primary Tauopathies.

Hybrid Tau-PET/MRI study: Quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET.

The underlying causes of eye movement disorders and ataxia.

Spatial Metabolic Covariance Networks in Progressive Supranuclear Palsy: Implications for Symptomatology and Their Neural Basis.

Deceleration Capacity as a Marker of Autonomic Cardiac Modulation in Prodromal and Manifest Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.

Barcelona Progressive Supranuclear Palsy (PSP) Registry: Clinical, Oculomotor, and Cerebrospinal Fluid Markers; from Suggestive to Definite Cases.

Neuronal-specific antibody in patients with multiple system atrophy and progressive supranuclear palsy.

A Mathematical Model of Cellular Aggregation Predicts Patterns of Tau Accumulation in Neurodegenerative Disease.

Reviewer Comment on Kazemi et al. "Assessment of Clinical and Demographic Factors Influencing the Severity of Levodopa-Induced Dyskinesia".

Toward Biology-Driven Diagnosis of Atypical Parkinsonian Disorders.

Absence of STN Neuronal Activity during MER in DBS Surgery: Diagnostic and Clinical Implications.

LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopathies and synucleinopathies.

Comparing and combining TSPO-PET tracers in tauopathies.

Progressive supranuclear palsy against everyone else: a look into the specificity of MRI markers.

Investigating the impact of white matter hyperintensities on longitudinal progression in progressive supranuclear palsy.

Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.

A Short Version of Carers' Quality of Life Questionnaire for Parkinsonism: Data from Progressive Supranuclear Palsy Network.

Protein fingerprints of brain-derived extracellular vesicles predict types of tau pathology.

Brain linear measurement index in the differential diagnosis between idiopathic normal pressure hydrocephalus and progressive supranuclear palsy.

Immune system modifications in atypical parkinsonism related to autoimmunity - a case control study.

No anti-IgLON5 antibody in carefully diagnosed PSP patients with "atypical" or variant clinical features.

Polyneuropathy in Parkinson's disease and atypical Parkinsonian syndromes: clinical impact and risk factors.

A Case of Progressive Supranuclear Palsy with Predominant Speech/Language Disorder.

Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology.

A novel lncRNA FAM151B-DT regulates degradation of aggregation prone proteins.

Cross-sectional and longitudinal validation of short and long versions of the progressive supranuclear palsy quality of life scale.

A Biomarker-Based Classification of Corticobasal Syndrome.

[Classification and Clinical Characteristics of Dementia].

Visual interpretation of [18F]Florzolotau Tau-PET imaging for differentiating alzheimer's disease and progressive supranuclear palsy.

A Bayesian analysis of diagnostic timelines across Alzheimer's disease, frontotemporal dementia, and other neurodegenerative conditions.

Understanding Tau pathology: Insights from animal models.

AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open-Label Extension on Safety, Biomarkers, and Disease Progression.

Imaging of Proteinopathies in the Brains of Parkinsonian Disorders.

Disease-specific tau polymorphs define unique protein interaction networks across proteinopathies.

CNS-Tau Specific Antibodies Illuminate Disease Signatures Across Tauopathies.

Dynamic Stability Analysis of Progressive Supranuclear Palsy Affected Gait Using Lyapunov Floquet Theory.

Facilitated α-synuclein oligomer sharing among glial cells by a centrally acting connexin inhibitor attenuates a rapidly progressive multiple system atrophy-cerebellar type model by reducing the neuronal α-synuclein burden.

The Progressive Supranuclear Palsy Clinical Deficits Scale accurately reflects functional as well as patient- and caregiver-reported outcomes.

[18F]THK5351 uptake in multiple system atrophy compared with other parkinsonian disorders.

Neuroanatomical normative modelling in frontotemporal lobar degeneration: higher heterogeneity in the behavioural variant.

Elevated levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 in multiple system atrophy: a marker of disease-associated microglial activation.

α-Synuclein seed amplification assay positivity beyond synucleinopathies.

Low synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease.

Quantitative Susceptibility Mapping and Iron Deposition in Autopsy-Confirmed Progressive Supranuclear Palsy.

The temporal order of genetic, environmental, and pathological risk factors in Parkinson's disease: paving the way to prevention.

Circadian Rhythms of Sleep-Wake, Thermoregulatory and Cardiovascular Function in Progressive Supranuclear Palsy.

The "gunslinger" sign in neurological disorders.

A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome.

Midsagittal Midbrain Area and Midbrain-to-Pons-Ratio Cannot Distinguish Overlap Syndromes Between Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy.

Digital speech assessments and machine learning for differentiation of neurodegenerative diseases.

Enhancing interpretability of AI with radiomics-based deep neural network: proof of concept in the classification of Parkinsonian syndromes with 18F-FDG PET imaging.

Incidence and Prevalence of Frontotemporal Dementia: A Systematic Review and Meta-Analysis.

Acetylation Mimetic and Null Mutations Within the Filament Core of P301L Tau Have Varied Effects on Susceptibility to Seeding and Aggregation.

Prevalence and correlated factors of REM sleep behavior disorder in patients with progressive supranuclear palsy.

Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.

Progressive Supranuclear Palsy-A Global Review.